Milestone COO granted 204,000 stock options at $1.96

Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Operating Officer.

Rhea-AI Filing Summary

Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Operating Officer. The filing corrects the exercise price on previously reported employee stock options and confirms a grant of 204,000 options with an exercise price of $1.96 per common share.

The options expire on February 2, 2036. One-fourth of the shares underlying the option vest on February 2, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, as long as the executive continues providing service through each vesting date.

Insider Trade Summary

Grant/Award: 204,000 shares

Grant/Award 1 txn

Insider Nelson Jeffrey Edward

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	204,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 204,000 contracts (Direct)

Footnotes (2)

1. F1. The exercise price on the initial filings was incorrectly stated.
2. F2. One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Milestone Pharmaceuticals (MIST) report in this Form 4/A?

Milestone Pharmaceuticals reported an amended insider filing for its Chief Operating Officer, reflecting an employee stock option grant for 204,000 common share options at an exercise price of $1.96 per share, expiring on February 2, 2036, subject to a service-based vesting schedule.

Why was the Milestone Pharmaceuticals (MIST) Form 4 amended?

The Form 4 was amended because the exercise price on the initial filings was incorrectly stated. This amendment corrects that error and confirms the accurate exercise price of $1.96 per share for the 204,000 employee stock options granted to the Chief Operating Officer.

What is the exercise price and term of the COO’s stock options at Milestone Pharmaceuticals (MIST)?

The Chief Operating Officer’s employee stock options have an exercise price of $1.96 per common share. These options are scheduled to expire on February 2, 2036, providing a long-dated right to purchase shares if vesting and other conditions are satisfied.

How do the 204,000 Milestone Pharmaceuticals (MIST) options vest for the COO?

One-fourth of the shares subject to the option vest on February 2, 2027. The remaining shares vest in equal monthly installments over the next 36 months, provided the Chief Operating Officer continues to provide service through each applicable vesting date.

Who is the reporting person in the Milestone Pharmaceuticals (MIST) Form 4/A filing?

The reporting person is Milestone Pharmaceuticals Inc.’s Chief Operating Officer, identified as an officer of the issuer. The Form 4/A is signed by Joseph Oliveto as Attorney-in-Fact, indicating he is authorized to sign on behalf of the reporting person for this transaction.

What type of security is reported in the Milestone Pharmaceuticals (MIST) Form 4/A?

The filing reports an employee stock option, described as a right to buy common shares of Milestone Pharmaceuticals. The option covers 204,000 underlying common shares, with a $1.96 exercise price, a February 2, 2036 expiration date, and a multi-year service-based vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 04:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nelson Jeffrey Edward

(Last) (First) (Middle)

C/O MILESTONE PHARMACEUTICALS INC.

1111 DR. FREDERIK-PHILIPS BLVD, STE 420

(Street)

MONTREAL A8 H4M 2X6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Milestone Pharmaceuticals Inc. [ MIST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.96(1)	02/02/2026		A		204,000		(2)	02/02/2036	Common Shares	204,000	$0	204,000	D

Explanation of Responses:

1. The exercise price on the initial filings was incorrectly stated.

2. One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

	/s/ Joseph Oliveto, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.